Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Sino Biopharmaceutical Limited
  6. News
  7. Summary
    1177   KYG8167W1380

SINO BIOPHARMACEUTICAL LIMITED

(1177)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sino Biopharmaceutical Limited Announces IND Application of Innovative Medicine "Tcr1672" Filed with and Accepted by FDA

10/08/2021 | 12:10am EST

The board of directors of Sino Biopharmaceutical Limited announced that an investigational new drug ("IND") application of the innovative medicine "TCR1672" self-developed by the Group has been filed with and accepted by the United States Food and Drug Administration ("FDA"). TCR1672 is a second-generation, highly selective P2X3 receptor antagonist mainly used in the treatment for adult patients with refractory chronic cough (RCC), and patients with complex visceral pain such as endometriosis pain. P2X3 receptor is a ligand-gated ion channel in the purine receptors family. Studies have shown that over-activation of P2X3 receptor is associated with hyper-sensitization of sensory neurons. Excessive, persistent and frequent coughs can be caused by injury or infection-induced hypersensitivity of airway and lung neurons. TCR1672 blocks the calcium ion influx from P2X3 receptor initiated by adenosine triphosphate (ATP), thereby exerting its specific inhibitory action to achieve therapeutic effect. To date, no P2X3 inhibitors have been approved in any country, and the related products have significant market potentials. The launch of the TCR1672 clinical trial will further enrich the Group's innovative product pipeline in the fields of respiratory diseases and analgesia, and bring new hope to patients.


ę S&P Capital IQ 2021
All news about SINO BIOPHARMACEUTICAL LIMITED
12/01Sino Biopharmaceutical Limited Enters into A Facility Agreement
CI
11/18Treadwell Therapeutics Inc. announced that it has received $91 million in funding from ..
CI
11/08Sino Biopharmaceutical Repurchases 5 Million Shares
MT
11/03Sino Biopharm Repurchases 3.5 Million Shares
MT
11/03Sino Biopharmaceutical Buys Back 1.7 Million Shares
MT
10/18SINO BIOPHARMACEUTICAL : Biopharm's Antibiotic Wins Marketing Approval in China
MT
10/15Sino Biopharmaceutical Limited Announces Approval for the First Generic "Colistimethate..
CI
10/08SINO BIOPHARMACEUTICAL : Anti-Tumor Drug Registration Accepted in China
MT
10/08SINO BIOPHARMACEUTICAL : Gets US FDA Nod for Clinical Trial of Cough, Pain Treatment
MT
10/08Sino Biopharmaceutical Limited Announces IND Application of Innovative Medicine "Tcr167..
CI
More news
Analyst Recommendations on SINO BIOPHARMACEUTICAL LIMITED
More recommendations
Financials
Sales 2021 34 160 M 4 383 M 4 383 M
Net income 2021 11 001 M 1 411 M 1 411 M
Net cash 2021 11 702 M 1 502 M 1 502 M
P/E ratio 2021 10,6x
Yield 2021 2,35%
Capitalization 107 B 13 718 M 13 719 M
EV / Sales 2021 2,79x
EV / Sales 2022 2,23x
Nbr of Employees 24 443
Free-Float 52,2%
Chart SINO BIOPHARMACEUTICAL LIMITED
Duration : Period :
Sino Biopharmaceutical Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SINO BIOPHARMACEUTICAL LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Last Close Price 5,70 HKD
Average target price 10,57 HKD
Spread / Average Target 85,4%
EPS Revisions
Managers and Directors
Yi Li Chief Executive Officer & Executive Director
Theresa Tse Chairman
Hsuan Tse General Manager-Information Management
Wei Nong Ye General Manager-Research & Development
Mao Li Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
SINO BIOPHARMACEUTICAL LIMITED-24.00%13 718
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641